USPH grows visits and buys clinics, but costs squeeze profit
Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.
It is the core new earnings result and explains the mixed pressure on USPH's price.
Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.
It is the newest strategic driver management is betting on for future growth.
New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.
It is a genuinely new company event that removes an overhang on the stock.
Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.
It shows the growth engine and its financing cost, a real counterweight for investors.